Latham & Watkins advises Phathom Pharmaceuticals in pricing of US$130 million public offering of common stock.Phathom Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
